Krzysztof Kiryluk

Krzysztof Kiryluk

Auto-generated profile, based on publicly available information

Krzysztof Kiryluk

Division of Nephrology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Kidney International
Verified
Journal Article
Closed access
PDF file
RMRiccardo Magistroni
Riccardo Magistroni
VDVivette D. D’aGati
Vivette D. D’aGati
GAGerald B. Appel
Gerald B. Appel
KKKrzysztof Kiryluk
Krzysztof Kiryluk

1 July 2011 in Kidney International
Verified
Journal Article
Closed access
PDF file
KKKrzysztof Kiryluk
Krzysztof Kiryluk
ZMZina Moldoveanu
Zina Moldoveanu
JSJohn T. Sanders
John T. Sanders
TET. Matthew Eison
T. Matthew Eison
HSHitoshi Suzuki
Hitoshi Suzuki
RWRobert J. Wyatt
Robert J. Wyatt

19 February 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
NLNiall J. Lennon
Niall J. Lennon
LKLeah C. Kottyan
Leah C. Kottyan
CKChristopher Kachulis
Christopher Kachulis
Noura Abul-HusnNoura Abul-Husn
Noura Abul-Husn
JAJosh Arias
Josh Arias
EKEimear E. Kenny
Eimear E. Kenny
Polygenic risk scores (PRSs) have improved in predictive performance, but several challenges remain to be addressed before PRSs can be implemented in the clinic, including reduced predictive performance of PRSs in diverse populations, and the interpretation and communication of genetic results to both providers and patients. To address these challenges, the National Human Genome Research Institute-funded Electronic Medical Records and Genomics (eMERGE) Network has developed a framework and pipeline for return of a PRS-based genome-informed risk assessment to 25,000 diverse adults and children as part of a clinical study. From an initial list of 23 conditions, ten were selected for implementation based on PRS performance, medical actionability and potential clinical utility, including cardiometabolic diseases and cancer. Standardized metrics were considered in the selection process, with additional consideration given to strength of evidence in African and Hispanic populations. We then developed a pipeline for clinical PRS implementation (score transfer to a clinical laboratory, validation and verification of score performance), and used genetic ancestry to calibrate PRS mean and variance, utilizing genetically diverse data from 13,475 participants of the All of Us Research Program cohort to train and test model parameters. Finally, we created a framework for regulatory compliance and developed a PRS clinical report for return to providers and for inclusion in an additional genome-informed risk assessment. The initial experience from eMERGE can inform the approach needed to implement PRS-based testing in diverse clinical settings.

30 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JXJingyuan Xie
Jingyuan Xie
LLLili Liu
Lili Liu
NMNikol Mladkova
Nikol Mladkova
YLYifu Li
Yifu Li
HRHong Ren
Hong Ren
KKKrzysztof Kiryluk
Krzysztof Kiryluk
Membranous Nephropathy (MN) is a rare autoimmune cause of kidney failure. Here we report a genome-wide association study (GWAS) for primary MN in 3,782 cases and 9,038 controls of East Asian and European ancestries. We discover two previously unreported loci, NFKB1 (rs230540, OR = 1.25, P = 3.4 × 10−12) and IRF4 (rs9405192, OR = 1.29, P = 1.4 × 10−14), fine-map the PLA2R1 locus (rs17831251, OR = 2.25, P = 4.7 × 10−103) and report ancestry-specific effects of three classical HLA alleles: DRB1*1501 in East Asians (OR = 3.81, P = 2.0 × 10−49), DQA1*0501 in Europeans (OR = 2.88, P = 5.7 × 10−93), and DRB1*0301 in both ethnicities (OR = 3.50, P = 9.2 × 10−23 and OR = 3.39, P = 5.2 × 10−82, respectively). GWAS loci explain 32% of disease risk in East Asians and 25% in Europeans, and correctly re-classify 20–37% of the cases in validation cohorts that are antibody-negative by the serum anti-PLA2R ELISA diagnostic test. Our findings highlight an unusual genetic architecture of MN, with four loci and their interactions accounting for nearly one-third of the disease risk.

2 June 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KKKrzysztof Kiryluk
Krzysztof Kiryluk
JNJan Novak
Jan Novak
IgA nephropathy (IgAN) represents the leading cause of kidney failure among East Asian populations and the most frequent form of primary glomerulonephritis among Europeans. Patients with IgAN develop characteristic IgA1-containing immune complexes that deposit in the glomerular mesangium, producing progressive kidney injury. Recent studies define IgAN as an autoimmune trait of complex architecture with a strong genetic determination. This Review summarizes new insights into the role of the O-glycosylation pathway, anti-glycan immune response, mucosal immunity, antigen processing and presentation, and the alternative complement pathway in the pathogenesis of IgAN.

19 June 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KKKrzysztof Kiryluk
Krzysztof Kiryluk
ESElena Sanchez-Rodriguez
Elena Sanchez-Rodriguez
XZXu-Jie Zhou
Xu-Jie Zhou
FZFrancesca Zanoni
Francesca Zanoni
LLLili Liu
Lili Liu
AGAli G. Gharavi
Ali G. Gharavi